HAVE CONFIDENCE IN YOUR REFERRALS

Visual Solutions, LLC is dedicated to assisting the dental professional by providing comprehensive tools to properly and confidently screen their patients for oral precancer and cancer.

MARKER 1

MARKER 1

Precancerous and cancerous cells have a greater concentration of nuclear material than normal cells. Additionally, during carcinogenesis the electrical property of diseased cells changes. Marker 1 attaches to nuclear material (such as DNA & RNA) and differentially stains these tissues in a process called “Metachromasia”. This allows you to easily identify suspicious lesions with high sensitivity by observing the blue fluorescence produced by Marker 1 when excited by UV light.

MARKER 2

MARKER 2

After Marker 1 highlights a suspicious lesion, Marker 2 confirms and increases the level of concern. Marker 2 attaches to cell surface carbohydrate chains associated with glycoproteins and glycolipids. Cancer uniquely alters glycol molecules on the surface of precancerous and cancer cells. This allows you to identify early stage disease changes with high specificity by observing green fluorescence produced by Marker 2 when excited by Blue light.

HOW IT HELPS YOU

ESPýOC™ Oral Mucosal Viewing and Marking System (patent pending) incorporates UV tissue auto fluorescence technology with fluorescent stains / molecular probes to highlight diseased lesions in the oral cavity with incredible sensitivity and specificity. The fluorescent stains identify high nuclear content areas while the molecular probe targets abnormal glycosylation, which is a property universal to carcinogenesis. By targeting DNA/RNA rich areas and cell surface tumor related glycan signatures the device provides a mechanism for early identification and surveillance of oral cancer.

PROTECT YOUR PRACTICE

Failure to detect oral pathology (oral cancer) is the #2 malpractice lawsuit topic within the dental industry. Whether it be lack of tools or their performance, failure to detect oral cancer is no longer a fear.

PROVEN RESULTS

We’ve done the research so you don’t have to. In university supervised double-blinded clinical trials, ESPýOC™  had the lowest false positive and false negative rates of any oral cancer-screening product on the market today.

RESPONSIBILITY

You spend the most time in oral cavities so patients rely on you to catch oral cancer, and catch it early. Be prepared for the inevitable patient who shows signs of cancer. Detection is your repsonsibility.

STAY COMPETITIVE

Raise the bar in your crowded marketplace. Gaining new patients and keeping them is easier when you have a leading technology by your side to stay ahead of the competition.

CREATE REVENUE

Keep your business foundation in line with the retention of patients. ESPýOC™ will not only bring in direct revenue, but you’ll experience ancillary effects. The payment of appreciation when saving lives is an immeasurable benefit.

BEST FOR PATIENTS

Current turnaround time from detection to diagnosis is 180 days. That’s too long when it comes to oral cancer. Survival rates drop and re-occurrence rates rise if a patient doesn’t receive early diagnosis.